CN1240392C - 促进细胞活化的外用剂 - Google Patents
促进细胞活化的外用剂 Download PDFInfo
- Publication number
- CN1240392C CN1240392C CNB031088236A CN03108823A CN1240392C CN 1240392 C CN1240392 C CN 1240392C CN B031088236 A CNB031088236 A CN B031088236A CN 03108823 A CN03108823 A CN 03108823A CN 1240392 C CN1240392 C CN 1240392C
- Authority
- CN
- China
- Prior art keywords
- polysaccharide
- aqueous solution
- polysaccharides
- cell activation
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000020411 cell activation Effects 0.000 title claims abstract description 11
- 230000001737 promoting effect Effects 0.000 title claims abstract description 11
- 150000004676 glycans Chemical class 0.000 claims abstract description 32
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 32
- 239000005017 polysaccharide Substances 0.000 claims abstract description 32
- 239000007864 aqueous solution Substances 0.000 claims abstract description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 10
- 229920002000 Xyloglucan Polymers 0.000 claims abstract description 10
- 239000008103 glucose Substances 0.000 claims abstract description 10
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 7
- 229920002307 Dextran Polymers 0.000 claims abstract description 7
- 239000001814 pectin Substances 0.000 claims abstract description 7
- 229920001277 pectin Polymers 0.000 claims abstract description 7
- 235000010987 pectin Nutrition 0.000 claims abstract description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 5
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 239000001103 potassium chloride Substances 0.000 claims description 6
- 235000011164 potassium chloride Nutrition 0.000 claims description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 241000512259 Ascophyllum nodosum Species 0.000 claims description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 14
- 201000010099 disease Diseases 0.000 abstract description 12
- 230000036039 immunity Effects 0.000 abstract description 9
- 210000002850 nasal mucosa Anatomy 0.000 abstract description 9
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 abstract description 8
- 229920001543 Laminarin Polymers 0.000 abstract description 8
- 239000005717 Laminarin Substances 0.000 abstract description 8
- 230000001413 cellular effect Effects 0.000 abstract description 8
- 210000000214 mouth Anatomy 0.000 abstract description 8
- 230000035876 healing Effects 0.000 abstract description 7
- 208000003265 stomatitis Diseases 0.000 abstract description 7
- 210000001519 tissue Anatomy 0.000 abstract description 6
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 210000004761 scalp Anatomy 0.000 abstract description 3
- 230000001568 sexual effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 24
- 210000003491 skin Anatomy 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 210000004927 skin cell Anatomy 0.000 description 8
- 230000003204 osmotic effect Effects 0.000 description 7
- 201000004384 Alopecia Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 210000003722 extracellular fluid Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 208000035985 Body Odor Diseases 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- 206010040904 Skin odour abnormal Diseases 0.000 description 3
- 231100000360 alopecia Toxicity 0.000 description 3
- 210000001700 mitochondrial membrane Anatomy 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 201000004647 tinea pedis Diseases 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 206010068168 androgenetic alopecia Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000002360 explosive Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- -1 sodium chloride Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 208000020663 Nasal mucosal disease Diseases 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 201000010618 Tinea cruris Diseases 0.000 description 1
- 206010067409 Trichophytosis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 210000002457 barrier cell Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000000969 xylosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Abstract
本发明涉及在水溶液中溶解了多糖类的促进细胞活化的外用剂，以整体重量比计，水溶液中添加了1～50%的木葡聚糖、1～50%的昆布多糖与1～50%的云芝多糖。在上述溶解了多糖类的水溶液中，以整体重量比计，还含有1～50%的果胶、1～30%的葡聚糖、1～30%的葡萄糖、1～40%的粘稠性多糖、1～30%的蘑菇多糖、1～50%的环糊精和1～50%的海藻糖。本发明可提高口腔或鼻粘膜等的细胞组织的免疫力或痊愈能力，且完全无副作用。不仅对花粉病或口炎，对皮肤或头皮等较广范围的细胞水平的各种疾病亦适用。
Description
技术领域
本发明涉及促进细胞活化的外用剂，该外用剂主要对花粉病或口炎等各种病症具有良好的缓解效果，同时利用细胞的电解质平衡和渗透压平衡使细胞活化，进而缓解皮肤细胞的细胞功能低下而引起的各种疾病。
背景技术
以往广泛使用氯化钠等无机盐、葡萄糖等天然糖或血浆等作为各种化妆品或医药外用剂的掺和剂。例如，美国专利3574854号公报记载了含有氯化钠等的柔肤霜。西德专利公开公报第3327840号的说明书中记载了含有矿物盐类的皮肤清洁用品。美国专利3859436号公报中记载了使用混合有葡萄糖等对皮肤有润滑作用的糖成分的技术方案。此外，美国专利3777597号公报中记载了剃须用葡聚糖水溶液。
然而，这些传统外用剂即使具有皮肤杀菌及保护皮肤的作用，但难以缓解因皮肤毛细管循环及功能低下所引发的皮肤病，即，色素沉淀、足癣、股癣、发癣菌病、狐臭、脱发症、头皮屑、痒等皮肤细胞分裂而使功能下降所引发的各种疾病。
因此，本发明者发明了可活化皮肤细胞，缓解因皮肤细胞的细胞功能低下所引发的各种疾病，可在皮肤表面形成与皮肤细胞间质液相同的环境，并可利用电解质平衡和渗透压平衡促进包括皮肤表面在内的障碍细胞正常化的水性皮肤及毛发化妆品(专利第1597430号)。
该水性皮肤及毛发化妆品在出现褐斑和红脸现象时可刺激皮下细胞使其分裂进而起到治疗作用。对头皮和狐臭等则通过渗透压作用刺激毛母细胞进而获得促进毛发生长及去狐臭的效果。即，该水性皮肤及毛发化妆品对脱发症的治疗率为83％，对色素沉淀的治疗率为95％，对红脸症的治疗率为53％。
然而，这些效果主要针对于皮肤或毛发。本发明者希望能够活化皮肤细胞等，在无副作用的条件下使粘膜细胞活化，对于因口腔粘膜病症所引发的口炎或因鼻粘膜障碍所引发的花粉病等疾病的治疗有效。
因此，本发明者发明了一种促进细胞活化的外用剂，该外用剂作为口腔或鼻粘膜的外用剂使用时无副作用。例如，适用于口炎或花粉病等较广范围的细胞水平的各种疾病(专利第2681527号)。该促进细胞活化的外用剂是添加了葡聚糖等多糖类和葡萄糖、α-1，3-1，6-葡聚糖、蘑菇多糖等的试剂。该促进细胞活化的外用剂对口炎的治疗为100％，对花粉病的治疗率为100％。
然而，上述促进细胞活化的外用剂对花粉病的治疗率是以40个人为对象时显示的。其后随着花粉病患者的急速增加，对花粉病的治疗率有渐渐降低的倾向。即，起初(平成2年)的效能试验中，对花粉病显示100％的治疗率，其后经过数十年，目前其治疗率与发病率的爆发性增加成反比例急速下降。花粉病的发病原因虽未明确，但推测是个人原因对口腔或鼻粘膜等的细胞产生某种影响而诱发该疾病。因此，可推测欲提高口腔或鼻粘膜等的免疫力或痊愈能力，必须保持细胞组织的健康状态，防止各种因素造成的不良影响，籍此抑制急速增加的花粉病的发病，同时显现治疗效果。
本发明提供一种对作为已有技术的促进细胞活化的外用剂进行了改良的外用剂。该外用剂可提高口腔或鼻粘膜等的免疫力或痊愈能力，且无副作用，不仅适用于花粉病或口炎的治疗，还适用于其他皮肤或头皮等较广范围的细胞水平的各种疾病的治疗。
发明内容
为了达到上述目的，本发明涉及将多糖类溶于水溶液而获得的促进细胞活化的外用剂，以整体重量比计，该水溶液中添加了1～50％的木葡聚糖、1～50％的昆布多糖与1～50％的云芝多糖。
上述溶解了多糖类的水溶液中，以整体重量比计，含有1～50％的果胶、1～30％的葡聚糖、1～30％的葡萄糖、1～40％的粘稠性多糖、1～50％的环糊精、1～30％的蘑菇多糖和1～50％的海藻糖。
上述溶解了多糖类的水溶液中，以整体重量比计，还可添加0.1～1％的氯化钠、0.1～1％的氯化钙与0.1～1％的氯化钾。
作为人类皮肤病变的炎症、色素沉淀、脱发等各种症状的起因与紫外线、化学物质等各种因素有关，其限于细胞水平的变化的实质是作为细胞内小器官之一的粒线体膜和细胞膜的障碍。即，粒线体膜的障碍引发细胞内呼吸受阻，进而降低作为细胞能源的ATP(腺苷三磷酸)的产生。因ATP的不足引发细胞膜能量运输功能的下降，从而降低细胞与间质液间的物质输送能力。其结果是，造成细胞内葡萄糖等营养物质的不足，进而出现与ATP的酸性下降有关的循环不佳。
产生上述细胞水平的变化的原因有许多，特别是对口腔或鼻粘膜等的细胞而言，渗透压作用可增加细胞间质液，使疾病部位的细胞活化。且，通过添加木葡聚糖、昆布多糖和云芝多糖，可提高口腔或鼻粘膜等的细胞组织的免疫力或痊愈能力。
具体实施方式
本发明的外用剂的基本配比是在溶有多糖类的水溶液中，以整体重量比计，添加1～50％的木葡聚糖、1～50％的昆布多糖与1～50％的云芝多糖。
木葡聚糖是普遍存在于伸长肥大的植物细胞的细胞壁(一次壁)的糖链。植物种类的特异性因半乳糖或岩藻糖-半乳糖与木糖残基结合而产生。该半乳糖残基及岩藻糖残基虽分别可与植物凝血素结合，但对这些分枝糖链的功能则未知。植物细胞的成长因来自细胞所具有的渗透压的吸水现象而产生，吸水力则由细胞壁的松弛引起壁压减少所产生。细胞壁松弛原因虽未知，但细胞的伸长常会引起木葡聚糖的分解与溶解，它作为管理细胞生理活性的多糖类之一而受注目。
昆布多糖被分类为碳水化合物之一的β葡聚糖，包含在以香菇为主的蕈类或昆布等海草类中，它具有提高免疫力的效果。已知其很难被单独吸收，必须与蛋白质一起被摄取。
云芝多糖可作为增强人类癌细胞的HLA等级I抗原的表现的免疫治疗医药品使用，可从河原蕈菌丝体萃取。该云芝多糖已被确认对胃癌、结肠·直肠癌、小细胞肺癌等肿瘤疾病的免疫和治疗有用。
本发明者从众多多糖类中，挑选出适用于外用剂的成分，其结果是，组合使用木葡聚糖、昆布多糖和云芝多糖，可调制出能够提高口腔或鼻粘膜等的细胞组织的免疫力或痊愈能力的外用剂。
溶解了上述多糖类的水溶液中，以整体重量比计，预先含有1～50％的果胶、1～30％的葡聚糖、1～30％的葡萄糖、1～40％的粘稠性多糖、1～30％的蘑菇多糖和1～50％的海藻糖。
果胶是作为植物细胞壁的构成成分的纤维素等与其他成分结合而使植物细胞结合的物质。它具有凝胶的作用，可用作本发明的外用剂的添加剂。
又，溶解了多糖类的水溶液中还可添加氯化钠、氯化钙与氯化钾。氯化钠的配比量对皮肤的渗透性平衡和电解质平衡有效。即，为使皮肤细胞活化，以整体重量比计，其含量为0.1～1％，同样地可在水溶液中溶解0.1～1％的氯化钙与0.1～1％氯化钾。
通过例举处方例及药理试验例对本发明的外用剂进行具体说明。
处方例1
葡聚糖 18
葡萄糖 10
环糊精 2
海藻糖 3
粘稠性多糖 7
蘑菇多糖 7
昆布多糖 2
云芝多糖 1
果胶 3
木葡聚糖 1
氯化钠 0.9
氯化钙 0.3
氯化钾 0.3
精制水 44.5
总计(重量比％) 100
所谓水相成分(纯水)系以纯水制造的无油状态的水，完全不含制造化妆品等常用外用剂时所使用的水溶性石油系表面活性剂等。因此，混合上述成分和水相成分时，为使上述成分完全溶解，操作温度最好为50～100℃。
表1所示为处方例1的效果。
表1
| 疾病名称 | 对象人数 | 有效性(点) | 有效率(％) |
| 男性脱发症 | 60 | 118 | 98 |
| 身心性脱发症 | 50 | 60 | 60 |
| 粉刺 | 30 | 58 | 97 |
| 红脸症 | 60 | 66 | 55 |
| 足癣 | 50 | 95 | 95 |
| 脂溢性皮炎 | 100 | 197 | 99 |
| 特应性皮炎 | 100 | 98 | 49 |
| 口炎 | 50 | 100 | 100 |
| 花粉病 | 100 | 196 | 98 |
表1所示为处方例1的药理试验的结果。此时的有效性是指使用本发明的外用剂后的效果，无变化为0点，有痊愈倾向为1点，确认有效果为2点，算出各人的合计点，以下式：有效率＝合计点/(对象人数×2)×100算出有效性。本次试验特别用于确认花粉病的治疗效果，以100个患者作为对象算出有效率。
其结果是，对于100人的花粉病的治疗有效率达到98％。起初(平成2年)的试验中，对花粉病的治疗有效率虽达到100％，但经过数十年到今天，其治疗有效率与发病率的爆发性增加成反比急速下降。故本发明可维持98％的有效率是特别值得一提的。又，600个病例中，确认没有出现副作用，且对男性脱发症、粉刺、足癣、脂溢性皮炎等很难医治的疾病极为有用。
由处方例2的配比调制出本发明的外用剂。
处方例2
葡聚糖 4
葡萄糖 3
环糊精 2
海藻糖 3
粘稠性多糖 3
蘑菇多糖 3
昆布多糖 2
云芝多糖 1
果胶 3
木葡聚糖 50
氯化钠 0.4
氯化钙 0.3
氯化钾 0.3
精制水 25
总计(重量比％) 100
其结果是，木葡聚糖的浓度如果提高至处方例2所示以上，则会出现溶解后分离的现象，作为处方来讲不理想。又，除了木葡聚糖之外，昆布多糖和云芝多糖中的任1种的浓度都必须至少达到1％以上才会显现出有效性，但如果浓度超过50％，则无法完成配方。
本发明通过在水相成分中添加以整体重量比计的1～50％的木葡聚糖、1～50％的昆布多糖与1～50％的云芝多糖，可提高口腔或鼻粘膜等的细胞组织的免疫力或痊愈能力，对花粉病等个人因素导致的疾病有治疗效果。
又，在提高细胞组织的免疫力或痊愈能力的同时，可形成与皮肤细胞间质液相同的环境，预防粒线体膜障碍所引发的细胞内呼吸障碍或作为细胞能源的ATP(腺苷三磷酸)产生下降，亦可保持电解质平衡和渗透压平衡，并促进皮肤细胞或粘膜细胞表层的障碍细胞的正常化，对男性脱发症、粉刺、足癣、脂溢性皮炎等很难治疗的疾病的治疗极为有用。
Claims (2)
1.促进细胞活化的外用剂，所述试剂通过多糖类溶于水溶液而获得，其特征在于，以整体重量比计，添加了1～50％的木葡聚糖、1～50％的昆布多糖与1～50％的云芝多糖、1～50％的果胶、1～30％的葡聚糖、1～30％的葡萄糖、1～40％的粘稠性多糖、1～30％的蘑菇多糖、1～50％的环糊精和1～50％的海藻糖。
2.如权利要求1所述的促进细胞活化的外用剂，其特征还在于，上述溶解了多糖类的水溶液中，以整体重量比计，还添加了0.1～1％的氯化钠、0.1～1％的氯化钙与0.1～1％的氯化钾。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002113217A JP3885204B2 (ja) | 2002-04-16 | 2002-04-16 | 細胞活性促進外用剤 |
| JP2002113217 | 2002-04-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1451389A CN1451389A (zh) | 2003-10-29 |
| CN1240392C true CN1240392C (zh) | 2006-02-08 |
Family
ID=29243346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031088236A Expired - Fee Related CN1240392C (zh) | 2002-04-16 | 2003-03-26 | 促进细胞活化的外用剂 |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP3885204B2 (zh) |
| CN (1) | CN1240392C (zh) |
| AU (1) | AU2003213370A1 (zh) |
| TW (1) | TWI254639B (zh) |
| WO (1) | WO2003086421A1 (zh) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005053841A (ja) * | 2003-08-05 | 2005-03-03 | Kyouto Biomedical Science:Kk | 皮膚外用剤 |
| CN1285382C (zh) * | 2004-12-20 | 2006-11-22 | 凌沛学 | 含海藻糖和玻璃酸的鼻腔用药传递系统及其制备方法 |
| DE102007052380A1 (de) * | 2007-10-31 | 2009-05-07 | Bitop Ag | Osmolythaltige Zubereitungen zur Anwendung bei trockenen Schleimhäuten |
| JP5620168B2 (ja) * | 2010-06-30 | 2014-11-05 | Ｄｓｐ五協フード＆ケミカル株式会社 | キシログルカン−カチオン複合体及びそれを含有する安定化組成物 |
| CN103239571B (zh) * | 2013-05-26 | 2014-09-03 | 广州市云桥生物科技有限公司 | 一种用于治疗斑秃的中药有效部位组合物及其制备方法 |
| JP6313118B2 (ja) * | 2014-05-16 | 2018-04-18 | 株式会社Cac | ＩｇＥ抑制剤 |
| MX387286B (es) * | 2015-09-29 | 2025-03-18 | Kimberly Clark Co | Composicion sinergica para el mantenimiento de un equilibrio saludable de la microflora. |
| GB2574534B (en) | 2017-02-28 | 2022-06-08 | Kimberly Clark Co | Synergistic composition for maintenance of healthy balance of microflora |
| FR3064473B1 (fr) * | 2017-04-03 | 2021-02-12 | Basf Beauty Care Solutions France Sas | Ingredient protecteur de l'equilibre de la flore microbienne cutanee et/ou mucosale |
| BE1027425B1 (fr) * | 2019-07-01 | 2021-02-08 | Aquilon Pharmaceuticals | Composition inhalable comprenant de la cyclodextrine a utiliser dans le traitement d’inflammations nasales |
| DE212021000176U1 (de) * | 2021-10-16 | 2022-01-04 | Nantong Jujiu New Material Science and Technology Co., Ltd. | Mononukleare Zellkulturschale für peripheres Blut mit Yunzhi-Polysaccharid-Beschichtung |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03204804A (ja) * | 1989-12-28 | 1991-09-06 | Mitsui Toatsu Chem Inc | 皮膚化粧料 |
| JP2681527B2 (ja) * | 1990-02-15 | 1997-11-26 | ジャパンファインケミカル株式会社 | 細胞活性促進外用剤 |
| DE19710368A1 (de) * | 1997-03-13 | 1998-09-17 | Henkel Kgaa | Verwendung von wasserlöslichen beta-Glucanen als Wirkstoffe zur Herstellung von therapeutischen Mitteln zur Hautbehandlung |
| JP2002275046A (ja) * | 2001-03-23 | 2002-09-25 | Kanebo Ltd | 表皮透過バリア強化剤及び皮膚外用組成物。 |
-
2002
- 2002-04-16 JP JP2002113217A patent/JP3885204B2/ja not_active Expired - Lifetime
-
2003
- 2003-02-20 TW TW092103549A patent/TWI254639B/zh not_active IP Right Cessation
- 2003-03-05 AU AU2003213370A patent/AU2003213370A1/en not_active Abandoned
- 2003-03-05 WO PCT/JP2003/002536 patent/WO2003086421A1/ja not_active Ceased
- 2003-03-26 CN CNB031088236A patent/CN1240392C/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| TWI254639B (en) | 2006-05-11 |
| AU2003213370A1 (en) | 2003-10-27 |
| TW200407154A (en) | 2004-05-16 |
| JP2005289815A (ja) | 2005-10-20 |
| WO2003086421A1 (fr) | 2003-10-23 |
| HK1060048A1 (zh) | 2004-07-30 |
| CN1451389A (zh) | 2003-10-29 |
| JP3885204B2 (ja) | 2007-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9629856B2 (en) | Compositions and methods for the treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds | |
| JP2681527B2 (ja) | 細胞活性促進外用剤 | |
| CN1240392C (zh) | 促进细胞活化的外用剂 | |
| EP2953628B1 (en) | Basidiomycete-derived cream for treatment of skin diseases | |
| TWI278318B (en) | External preparations for treating dermatitis | |
| KR0181763B1 (ko) | 피부염의 치료외용제 | |
| ES2876331T3 (es) | Composición de gel oral que comprende quitosano, pectina, L-carnitina y N-acetilcisteína | |
| JP6381641B2 (ja) | 皮膚における外部刺激応答の鎮静化剤又は鎮静化方法 | |
| CN113876788A (zh) | 红景天苷水凝胶制剂及其制备方法和应用 | |
| HK1060048B (zh) | 促进细胞活化的外用剂 | |
| JP2004256410A (ja) | パーマネントウェーブ剤 | |
| RU2407535C2 (ru) | Биологически-активное средство для лечения дерматозов | |
| KR0141930B1 (ko) | 세포활성촉진 외용제 | |
| RU2316333C1 (ru) | Биологически активная добавка к средству для оздоровительно-восстановительных косметических панто-магниевых ванн и средство для оздоровительно-восстановительных косметических панто-магниевых ванн на ее основе | |
| HK1060981B (zh) | 治疗皮肤炎之外用剂 | |
| HK1004979B (zh) | 含治疗皮炎外用药的肾上腺皮质类固醇 | |
| HK1233528A1 (zh) | 操作後的皮肤护理系统、组合物及其使用方法 | |
| MX2009012091A (es) | Formulacion antimicotica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1060048 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060208 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |